Lawyers
Jordana Sanft

About

Contact

Assistant Contact

T416-596-1083

M416-317-4613

Ejsanft@litigate.com

Add to Outlook Contacts

Expertise

Practice Areas:
- Intellectual Property
- Commercial Litigation
Bar Admissions:
- Ontario (2001)
Education:
- McGill University (1999) BCL/LLB
- Tufts University (1995) BA

Details

Bio
Cases
Associations
Blog Posts
News & Media
Publications & Presentations
Recognition

Jordana Sanft (she/her)

is a partner at Lenczner Slaght.

"Jordana draws upon her experience, technical expertise, advocacy skills, and comprehensive understanding of the law to deliver the best results for her clients." — Chambers Canada

Jordana is a leading litigator with over 25 years of experience in complex, high-stakes disputes, from patent, trademark, and copyright litigation to commercial disputes and judicial review. She co-leads the firm's Intellectual Property group. Jordana is known for creative, pragmatic litigation strategies grounded in deep technical and industry knowledge and a thorough understanding of her clients' business objectives. She treats her clients as partners, acting as a trusted adviser from the earliest stages of a dispute through to its resolution and achieving successful results in and out of the courtroom.

Jordana regularly acts in patent impeachment and infringement actions, including proceedings under the Patented Medicines (Notice of Compliance) Regulations, and has particular expertise in the pharmaceutical and life sciences industry, having worked on some of the most complex cases in Canada. Jordana led the first precedent-setting challenges under the amended PM(NOC) Regulations. She also represents clients in judicial review proceedings, including challenges to administrative decisions and delegated legislation, regulatory matters, and damages actions. Her litigation practice extends across a wide range of industries, including technology, biotechnology, infrastructure, consumer products, energy, packaged goods, hospitality, and agriculture. She is particularly sought after by clients who put innovation and technology at the core of their business.

Jordana engages closely with clients to align litigation strategy with their commercial objectives at the local and global level. She is experienced in coordinating multi-jurisdictional litigation and navigating the cross-border complexities that arise in global disputes. She advises clients on pre-litigation strategy, developing sophisticated and practical positions to achieve the strongest possible outcomes throughout the litigation lifecycle. Whether enforcing intellectual property rights or managing commercial disputes, Jordana brings the same rigour and strategic depth to every engagement.

Jordana is a recognized thought leader on emerging issues in IP and technology, including the intersection of intellectual property and artificial intelligence. She is deeply engaged in the legal and IP community as a committee member, Chair, Director, mentor, and frequent speaker and writer.

Jordana has appeared as counsel before the Federal Court of Appeal, the Federal Court, the Ontario Superior Court of Justice, and specialized tribunals including the Trademarks Opposition Board. She is a registered patent and trademark agent.

Recognized nationally and globally for her deep expertise, Jordana is trusted by clients as a powerful advocate who brings innovation, energy, and rigour to their most complex and commercially significant cases.

Genentech Inc and Hoffmann-La Roche Limited v Biosimilar Collaborations Ireland Limited

Counsel to Genentech Inc and Hoffmann-La Roche Limited in a PM(NOC) action in the Federal Court in respect of Canadian Patent Nos. 2,788,253 and 2,711,798.

Jordana Sanft, Andrew Moeser, Martin Brandsma, Corey McClary & Natalie Workewych | March 13, 2026

Hoffmann-La Roche Limited v The Minister of Health, Attorney General of Canada and Biosimilar Collaborations Ireland Limited

Counsel to Hoffmann-La Roche Limited in an application for judicial review in the Federal Court, in respect of a decision made by the Minister of Health and its continued course of conduct in respect of the filing of a new drug submission by Biosimilar Collaborations Ireland Limited.

Jordana Sanft, Andrew Moeser, Corey McClary & Natalie Workewych | February 27, 2026

Confidential Construction Arbitration

Counsel to a contractor against a sub contractor in a confidential construction arbitration relating to negligence, breach of contract, and damages arising from deficient installation of shoring and foundation systems.

Jordana Sanft, Andrew Parley, Aaron I. Grossman & Rachel Rowlands | March 2, 2026

Adeia Guides v BCE Inc, Ericsson et al

Counsel to Adeia Guides, Inc. and Adeia Media Holdings LLC in a patent infringement action involving four patents related to digital entertainment technologies.

Sana Halwani, Jordana Sanft, Andrew Moeser, Martin Brandsma, Kaitlin Soye, Veronica C. Tsou, Jim Lepore, Amber Blair, Jacqueline Chan, Dan Malone & Anna Hucman | December 16, 2021

Carol Rosenstein v Queen Productions Limited et al

Counsel for Carol Rosenstein in a dispute with Queen Productions Limited, Sony Music Entertainment, and Sony Music Entertainment Canada Inc. over the copyright infringement of several Queen music videos directed and produced by Bruce Gowers, including the music video for Bohemian Rhapsody.

Jordana Sanft, Sana Halwani & Sarah Gupta | December 6, 2024

Gilead Sciences, Inc et al v Apotex Inc

Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent Nos. 2,845,553 and 2,990,210.

Jordana Sanft, Sana Halwani, Cynthia L. Tape, Corey McClary, Alexis Vaughan, Devon R. Kapoor & Amber Blair | June 1, 2022

Gilead Sciences, Inc et al v Apotex Inc

Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.

Jordana Sanft, Sana Halwani, Cynthia L. Tape, Veronica C. Tsou, Martin Brandsma, Corey McClary, Alexis Vaughan & Amber Blair | June 1, 2022

Gilead Sciences Inc, et al v JAMP Pharma Corporation

Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.

Jordana Sanft, Martin Brandsma, Corey McClary, Alexis Vaughan & Amber Blair | July 19, 2022

Gilead Sciences, Inc et al v JAMP Pharma Corporation

Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,990,210.

Jordana Sanft, Jenene Roberts, Martin Brandsma, Corey McClary, Alexis Vaughan, Devon R. Kapoor & Amber Blair | August 4, 2022

Gilead Sciences, Inc et al v Natco Pharma (Canada) Inc

Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.

Jordana Sanft, Sana Halwani, Jenene Roberts, Veronica C. Tsou, Martin Brandsma, Corey McClary, Alexis Vaughan & Amber Blair | August 2, 2022

Natco Pharma (Canada) Inc v Canada (Health)

Counsel to Gilead Sciences Inc. in a judicial review proceeding in the Federal Court, which was the first ever challenge of data protection for anti-HIV combination drug therapies in respect of DESCOVY. Successfully upheld data protection. (Prior to joining Lenczner Slaght.)

Jordana Sanft | October 1, 1900

Alberta Innovates Technology Futures v Connacher Oil and Gas Limited

Counsel to Connacher Oil and Gas Limited in a patent infringement action commenced by Alberta Innovates-Technology Futures in regard to Canadian Patents 2 323 029 and 2 391 721. (Prior to joining Lenczner Slaght.)

Jordana Sanft | January 1, 2021

Premier Tech

Counsel to Premier Tech in regard to trademark portfolio strategy, pre-litigation advice and enforcement, opposition proceedings and other trademark prosecution matters, and trademark litigation. (Prior to joining Lenczner Slaght.)

Jordana Sanft | January 1, 2021

Genentech Inc. et al v Amgen Canada Inc.

Counsel to Hoffmann-La Roche Limited and Genentech, Inc. in various Federal Court actions under the new PMNOC Regulations in respect of trastuzumab (HERCEPTIN), which were the first actions under the new regime. (Prior to joining Lenczner Slaght.)

Jordana Sanft | September 1, 1900

Genentech Inc. et al v Celltrion Healthcare Co, Ltd.

Jordana Sanft | August 1, 1900

Eli Lilly v Various Generic Companies

Counsel to Eli Lilly and Company in various Federal Court proceedings in respect of teriparatide (FORTEO). (Prior to joining Lenczner Slaght.)

Jordana Sanft | July 1, 1900

Hoffmann-La Roche Limited and Genentech, Inc v Various Biosimilar and Generic Companies

Counsel to Hoffmann-La Roche Limited and Genentech, Inc. in various Federal Court proceedings in respect of bevacizumab (AVASTIN). (Prior to joining Lenczner Slaght.)

Jordana Sanft | June 1, 1900

Gilead Sciences Inc v Idenix Pharmaceuticals Inc

Counsel to Gilead Sciences Inc in the Federal Court and Federal Court of Appeal (leave to SCC denied) proceeding in respect of sofosbuvir, successfully invalidating Idenix’s ‘191 patent and maintaining Gilead’s ‘657 patent. (Prior to joining Lenczner Slaght.)

Jordana Sanft | May 1, 1900

Apotex Inc v Pfizer Canada Inc

Counsel to Pfizer in a summary judgment motion regarding latanoprost (XALATAN), successfully upholding the validity of Pfizer’s ‘132 patent on summary judgment. (Prior to joining Lenczner Slaght.)

Jordana Sanft | April 1, 1900

Merck & Co et al v Apotex Inc

Counsel to Merck & Co., et al in a patent infringement action in the Federal Court and Federal Court of Appeal (leave to SCC denied) relating to lisinopril. (Prior to joining Lenczner Slaght.)

Jordana Sanft | December 1, 2021

Merck & Co et al v Apotex Inc

Counsel to Merck & Co. and AstraZeneca in a damages reference action in the Federal Court regarding lisinopril and prinivil. (Prior to joining Lenczner Slaght.)

Jordana Sanft | December 1, 2021

Glaxosmithkline Inc et al v Pharmascience Inc et al

Counsel to Glaxosmithkline Inc. in various proceedings in the Federal Court including regarding valacyclovir hydrochloride (VALTREX). (Prior to joining Lenczner Slaght.)

Jordana Sanft | March 1, 1900

Glaxosmithkline Inc v Apotex Inc et al

Counsel to Glaxosmithkline in an action in the Federal Court regarding cefuroxime. (CEFTIN) (Prior to joining Lenczner Slaght.)

Jordana Sanft | May 1, 1900

Glaxosmithkline Biologics SA v Novartis

Counsel to Glaxosmithkline in an impeachment action in the Federal Court regarding adjuvant use in vaccines. (Prior to joining Lenczner Slaght.)

Jordana Sanft | May 1, 1900

Pfizer Canada Inc et al v Apotex Inc

Counsel to Pfizer in a section 8 case in the Federal Court regarding amlodipine (NORVSAC). (Prior to joining Lenczner Slaght.)

Jordana Sanft | May 1, 1900

Apotex Inc v Hoffman-La Roche Limited

Counsel for Roche in a section 8 action in the Federal Court regarding valganciclovir (VALCYTE). (Prior to joining Lenczner Slaght.)

Jordana Sanft | May 1, 1900

Bristol-Myers Squibb Canada Co et al v Teva Canada Limited et al

Counsel to Bristol-Myers and Merck in a PM(NOC) application in the Federal Court and Federal Court of Appeal regarding efavirenz (ATRIPLA). (Prior to joining Lenczner Slaght.)

Jordana Sanft | May 1, 1900

Bristol-Myers Squibb Canada Co et al v Mylan Pharmaceuticals ULC

Counsel to Bristol-Myers and Merck in a PM(NOC) application in the Federal Court and Federal Court of Appeal regarding efavirenz (SUSTIVA). (Prior to joining Lenczner Slaght.)

Jordana Sanft | May 1, 1900

Henry Neugebauer v Anna M Labieniec

Counsel to Mr. Neugebauer in the Federal Court and Federal Court of Appeal in a copyright dispute relating to joint authorship of book relating to a Memoire recounting Mr Neugebauer’s story as a Holocaust survivor. (Prior to joining Lenczner Slaght.)

Jordana Sanft | May 1, 1900

Fairmont Hotels Re Trademark Matters

Counsel to Fairmont Hotels in various trademark prosecution and litigation matters, including litigation matters to protect company trademarks and corporate name in the Federal Court, Opposition Board and pursuant to the Canada Business Corporations Act. (Prior to joining Lenczner Slaght.)

Jordana Sanft | February 1, 1900

Intellectual Property Institute of Canada - Executive Board-Treasurer (2025-2026); Director (2022-2024); Conference Committee Chair (2021-2023); Vice Chair (2019-2021); Women in IP Networking Group; Intervention Committee (2025-2028)
Canadian Bar Association - Intellectual Property Section; Federal Courts Bench and Bar Liaison Committee - Chair (2023-2025) and Member (2022-2023); IP Court Practice Committee - Chair (2017-2020) and Member (2021-present)
International Association for the Protection of Intellectual Property
The Toronto Intellectual Property Group
ChIPs - Non-profit organization advancing women in technology, law and policy
The York School - Risk Committee of the Board of Directors; Member at Large (2017-2022)
Youth Rising Above - Board Member (2021-2022)

Making a Splash in Patent Law: The Federal Court of Appeal Clarifies Overbreadth and Utility

ProSlide Technology and WhiteWater West Industries are the two largest competitors in the global water slide market. That competitive pressure has, perhaps inevitably, spilled into the courtroom.

Jordana Sanft, Jim Lepore & Natalie Workewych | March 23, 2026

25 for 25: IP Milestones from the Last Quarter Century

As 2025 draws to a close, we present a curated set of 25 turning points in Canadian intellectual property law from 2001–2025. Each entry touches on a key Canadian IP development and distills why it matters. These decisions, reforms, and treaty-driven changes moved the dial and continue to shape how businesses build IP portfolios, negotiate deals, and win disputes.

Jordana Sanft | December 17, 2025

DABUS Down, Not Done: Thaler Appeals Canadian Ruling on AI Inventorship

As we predicted in our earlier comment, Dr. Stephen Thaler – who created an AI system that allegedly conceived two disparate yet novel products – is not giving up his bid to have that system (DABUS) awarded a Canadian patent.

Jordana Sanft, Jim Lepore & Natalie Workewych | December 15, 2025

Robots Rejected: Canada Denies AI as Patent Inventor

The wait is over – the Canadian Patent Appeal Board (the Board) has answered the question we’ve been tracking since 2022: can an artificial intelligence (AI) system be named as an inventor on a Canadian patent application? That answer, delivered in Re Thaler, Stephen, is no.

Jordana Sanft, Jim Lepore & Catherine Blair | September 18, 2025

From Red Carpet to Rights: Top 5 IP Considerations for TIFF Goers

The Toronto International Film Festival (TIFF) isn’t just a red carpet for filmmakers – it’s a global marketplace where content creators, distributors, investors, business professionals, and film enthusiasts converge. Amid all the glitz and creative content, intellectual property (IP) issues may not be top of mind for many at TIFF, but a film’s journey from inception to screening should carefully curate relevant IP rights to avoid unhappy IP plot twists. In this post we discuss five practical IP considerations for navigating the film festival.

Jordana Sanft | September 10, 2025

Class Dismissed: Copyright Reverse Class Action Fails to Get Passing Grade

On July 16, 2025, a long-running effort by several film studios to have claims of copyright infringement decided by way of reverse class action reached a further impasse. In Voltage Pictures v Robert Salna (Voltage FCA #2), the Federal Court of Appeal (FCA) dismissed – for a second time – the studios’ appeal for certification of a proposed class of unknown individual defendants.

Jordana Sanft, Paul-Erik Veel & Martin Brandsma | July 24, 2025

North of Legal or South of Safe? Key Legal and Regulatory Considerations to Substantiate “Made in Canada” Claims

On the heels of Canada Day and with Canadian patriotism on the rise, many companies doing business in Canada are eager to promote their products as “Canadian”. Before wrapping a product in the Canadian flag, and to avoid common pitfalls, the legal and regulatory requirements for “Made in Canada” and “Canadian” claims should be considered.

Cynthia L. Tape & Jordana Sanft | July 2, 2025

Coming Soon: Changes to Trademark Proceedings in Canada

On April 1, 2025, various amendments to the Trademarks Act and Trademarks Regulations will come into force. The overarching theme of the upcoming amendments is to increase efficiency and effectiveness in trademark proceedings before the Trademarks Opposition Board (TMOB) and the Federal Court.

Jordana Sanft & Sarah Gupta | March 31, 2025

Humans are Central to Copyright: Highlights from the U.S. Copyrightability Report and its Potential Implications for Canada

The U.S. Copyright Office released a comprehensive report titled "Copyright and Artificial Intelligence Part 2: Copyrightability" (“U.S. Copyrightability Report”) in January 2025, which delves into the complex issue of copyright protection for AI-generated material.

Jordana Sanft | February 3, 2025

Health Canada’s Proposed Regulations Addressing Drug and Medical Device Shortages Now Open for Public Comment

Following on Health Canada’s plan to introduce new regulations aimed at addressing therapeutic product shortages as discussed previously in our Fall Regulatory Roundup, proposed amendments to the Food and Drug Regulations and Medical Device Regulations were published for public comment on December 28, 2024. The comment period closes on March 8, 2025.

Cynthia L. Tape & Jordana Sanft | January 29, 2025

AI in the Courtroom: The Quest for Legal Precedents

The current landscape is inundated with narratives surrounding artificial intelligence and its intersection with the law. From the New York Time’s lawsuit launched against OpenAI in December 2023, to the BC lawyer reprimanded for citing fake AI-generated cases, to the lying Air Canada chatbot, the legal and mainstream media is full of stories of AI or people using AI running up against traditional legal doctrine and practice. Yet, amidst this surge of AI-related incidents, Canada finds itself grappling with more questions than answers.

Sana Halwani, Jordana Sanft & Jim Lepore | April 18, 2024

Policing Scope Creep: Relevance in Canadian Pharma Disputes for Section 8 Damages

In Canada, a generic pharmaceutical company can commence an action for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the “Regulations”), if it successfully defends a patentee’s claims in an earlier section 6 prohibition proceeding. Section 8 actions are often complex, requiring a determination of the alleged loss suffered by assessing a “but-for world” where the generic would have received regulatory approval and commenced sales at an earlier date, but for having been blocked by the operation of the Regulations. Depending on the drug(s) and patent(s) at issue, there may be several independent section 8 actions against a patentee, each started by a different generic plaintiff (see our previous post). When distinct section 8 actions are commenced pertaining to the same drug(s), patent(s), and patentee(s), issues as to relevance and scope of each action may arise.

Jordana Sanft, Andrew Moeser & Martin Brandsma | April 12, 2024

Swiftly Navigating the Importance of IP

Few pop icons have navigated the art of protecting their intellectual property as well as Taylor Swift. Not only does Taylor Swift have an outstanding knack for creating number one hits, a keen eye for branding, and an entrepreneurial spirit that is inspiring, she is also business savvy in protecting her trademarks and copyright. On this International Women’s Day 2024 we look to Taylor Swift as an inspiration in IP protection, enforcement, and commercialization, as we celebrate women who “could show you incredible things”.

Jordana Sanft | March 6, 2024

Sniff, Kleenex Is Snuffed Out of Canada

On August 25, 2023, Canadians were advised that KLEENEX was blowing out of town and would no longer be available in Canada (see Globe & Mail article).

Jordana Sanft | August 30, 2023

No Human, No Copyright: U.S. District Court of Columbia Denies Thaler’s Summary Judgment Motion

The “Creativity Machine”, owned by Stephen Thaler, generated a work of art of its own accord. Thaler applied to register copyright in the artistic work titled ‘A Recent Entrance to Paradise’ with the United States Copyright Office. The application stated the Creativity Machine created the work and it was listed as the author. Thaler sought to transfer the copyright to himself as owner. The registration was denied.

Jordana Sanft | August 22, 2023

Insights on the Independence of Expert Evidence

In the recently released decision dTechs EPM Ltd v British Columbia Hydro and Power Authority and Awesense Wireless Inc, the Federal Court of Appeal (“FCA”) weighed in on the role and independence of experts in patent cases. In particular, the FCA provided guidance on (1) the role counsel may play in preparing expert reports; (2) an expert’s role in claim construction; and (3) the difference in the role of an expert where anticipation is alleged based on prior use versus prior publication.

May 31, 2023

Clarity on the Test for Inducing Infringement in Canadian Patent Law

Indirect infringement or “inducement” often arises in pharmaceutical patent infringement cases where a defendant generic manufacturer may not ultimately “use” the drug in question (i.e., directly infringe). Since 2011, the Federal Court of Appeal’s (“FCA”) Corlac Inc v Weatherford Canada Inc decision has frequently been cited as the leading authority for the tripartate test for inducement. In 2020, the Federal Court suggested that Corlac had changed the law of inducement—particularly at the second step determining influence—thereby requiring “a higher threshold for establishing inducement than was applied in the earlier cases”. In the recent decision of Teva Canada Limited v Janssen Inc (“Paliperidone”), the FCA has rejected that interpretation of Corlac. The FCA held that Corlac incorporates the same principles of inducing infringement as had been established in cases dating back to 1906. In doing so, it overturned the lower Court’s inducement determination based on a supposed higher standard and found that the defendant was liable for inducement when the Corlac test was properly applied.

Jordana Sanft, Andrew Moeser & Martin Brandsma | April 13, 2023

Let’s Chat(GPT)

The use of generative artificial intelligence (AI) is on the rise and is receiving significant attention across disciplines and industries. The impact of generative AI spans various fields such as healthcare, gaming, education, marketing, visual arts, literature, music, banking and fashion, to name few. In the context of intellectual property law, where the focus is on innovation and creativity, generative AI raises countless complex questions. This blog post focuses on ChatGPT and copyright.

Jordana Sanft | March 1, 2023

To Consolidate or Not to Consolidate – This is the Federal Court’s Question

In a recent decision, Takeda Canada Inc v Apotex Inc, the Federal Court dismissed the Plaintiff, Takeda’s, motion for consolidation of two actions against Apotex relating to Takeda’s dexlansoprazole (DEXILANT) under section 6 of the Patented Medicines (Notice of Compliance) Regulations (the “PM(NOC) Regulations”).

Jordana Sanft, Andrew Moeser & Amber Blair | January 30, 2023

Better Together – or Maybe Not

Some things just go better together and probably always will, as Luke Combs sings in ‘Better Together’. Like a cup of coffee and a sunrise; Sunday drives and time to kill. Multiple section 8 actions however have not made the cut. According to the recent decision of Justice Southcott in Apotex Inc v Janssen Inc, multiple actions for section 8 damages should not have common issues heard together.

Jordana Sanft & Andrew Moeser | November 3, 2022

AI and IP: Who or What Can Be an Author or Inventor in Canada?

There have been two recent and notable developments with respect to artificial intelligence (“AI”) and intellectual property (“IP”) rights in Canada. A preliminary legal question at the intersection of AI and IP is whether AI can be granted authorship in the case of copyright or inventorship in the case of patents for something that it generated. Jurisdictions around the world are facing the same issues. This blog post discusses Canada’s first foray into this new frontier.

Jordana Sanft & Jenene Roberts | February 17, 2022

The Federal Court Clarifies the Burden of Proof in Summary Trial

In 2022, the use of summary proceedings in patent matters continues at the Federal Court. In Janssen Inc v Pharmascience Inc, the Court:

Jordana Sanft, Andrew Moeser & Kaitlin Soye | January 26, 2022

2021 Year in Review & 2022 Trends to Watch: Pharmaceutical Patents

In 2021, the Canadian pharmaceutical and life sciences industries were once again at the forefront of innovation, developing and commercializing new vaccines, drugs, and medical devices. The media continued to shine a light on the advances made to protect the public from COVID-19, including regulatory approvals for new mRNA and adenovirus vector vaccines. In the pharmaceutical patent litigation arena in particular, we saw some new trends develop. There were important developments in proceedings relating to pharmaceutical patents, advances in cases and legislative developments relating to the Patented Medicine Prices Review Board (“PMPRB”) as well as judicial review applications and appeals in patent-related fields.

Jordana Sanft | January 6, 2022

Lenczner Slaght Celebrates 25 Years on the Lexpert Bull’s-Eye

The 2026 Canadian Legal Lexpert Directory continues to recognize Lenczner Slaght as the #1 firm in Toronto for Litigation and Commercial Litigation.

March 17, 2026

Lenczner Slaght Recognized in World-Renowned Directory, Chambers Global

For the 24th consecutive year, Canada’s leading litigation firm and its expert litigators have been recognized in world-renowned directory, Chambers Global.

February 12, 2026

11 Lenczner Slaght Litigators Recognized in Lexpert 500 Cross Border

The 2026 edition of Lexpert's Leading 500 Cross-Border Lawyers features 11 of our preeminent lawyers, reflecting their exceptional advocacy and the trusted counsel they provide to clients navigating complex, high-stakes cross-border disputes.

January 15, 2026

Lenczner Slaght Recognized in Legal 500 Canada for Litigation Excellence

As Canada’s leading litigation firm, we are proud to maintain our Tier 1 ranking in Dispute Resolution in Legal 500 Canada.

December 1, 2025

Lenczner Slaght Recognized as Canada’s Leading Litigators

Based on an in-depth peer review process across the legal profession, 26 Lenczner Slaght lawyers are recognized in the 2025 Lexpert Special Edition: Canada’s Leading Litigation Lawyers for their exceptional advocacy and extensive courtroom experience.

November 20, 2025

Toronto Bar Asked to Remove Post Featuring Blue Jays Logo

Interviewed by CBC News, Jordana Sanft explains why businesses should avoid using sports team's logos without permission, and why it’s essential for brands to actively protect their own trademarks to prevent consumer confusion and dilution.

Jordana Sanft | October 27, 2025

Calling on the Feds to Close the Federal Courts’ Funding Gap

Jordana Sanft was featured in an article by the Canadian Bar Association’s National Magazine on the funding gap facing Canada's federal courts. Jordana reinforced the importance of having adequate resources to protect judicial independence, uphold the rule of law, and maintain public confidence in Canada's justice system.

Jordana Sanft | October 20, 2025

LMG Life Sciences Highlights Lenczner Slaght’s Expertise in Patent Litigation

Lenczner Slaght is proud to once again be recognized for its patent litigation expertise in the latest edition of LMG Life Sciences, following extensive qualitative research informed by client and peer feedback

October 2, 2025

Chambers Canada Highlights Lenczner Slaght’s Excellence in Advocacy

Canada’s leading litigation firm continues to be recognized in world-renowned directory, with new rankings highlighting its deep bench of expertise.

September 25, 2025

Lenczner Slaght Litigators Featured Among Best Lawyers in Canada

The 2026 edition of Best Lawyers in Canada recognizes Lenczner Slaght with 180+ rankings, featuring 48 of our expert litigators across 27 practice areas.

September 4, 2025

2025 Snapshot: Through the Lens of Lenczner Slaght

We’ve released our 2025 Snapshot, highlighting the most significant developments, decisions, and trends in litigation from the past year across 21 practice areas. Reflect on 2025 and look ahead to 2026 through the lens of our expert litigators.

February 12, 2026

Patent Agent Training Course: Infringement & Validity

Jordana Sanft served as a lead instructor at the Intellectual Property Institute of Canada’s Patent Agent Training Course: Infringement & Validity, on the Virtual Lectures and Workshops "Section 1: Patent Infringement", which took place from February 4-6. The program covered core principles of patent infringement and included hands-on exercises to deepen students' understanding of these key concepts.

Jordana Sanft | February 4, 2026

Effective Factum Writing

Jordana Sanft, Anna McAllister, and Kyle Magee were invited to speak at McGill University – Faculty of Law's integration workshop on “Effective Factum Writing."

Jordana Sanft, Anna McAllister & Kyle Magee | January 12, 2026

14th Annual University of Toronto Patent Colloquium

Jordana Sanft was invited to share her expertise at the University of Toronto’s annual Patent Colloquium. Jordana presented on the panel titled, Utility and Sound Prediction.

Jordana Sanft | November 14, 2025

IPIC 2025 Conference

Jordana Sanft was invited to moderate the session, Redefining Deference: Implications for IP Professionals, at the IPIC 2025 Conference. Jordana led a discussion on the recent judicial shifts reshaping standards of review for administrative decisions. The session focused on the Supreme Court of Canada’s 2024 rulings in Auer and TransAlta, which favours a reasonableness standard for subordinate legislation.

Jordana Sanft | October 9, 2025

IP Litigation in the AI Era: Challenges and Strategies

Jordana Sanft was invited to share her expertise at the Intellectual Property Institute of Canada (IPIC)'s AI & IP Law Webinar Series. Jordana spoke on the panel, IP Litigation in the AI Era: Challenges and Strategies where she discussed how artificial intelligence (AI) is reshaping the landscape of intellectual property litigation. The session covered both the opportunities and potential risks associated with using AI in trial preparation and during trial, while also addressing principles, practice directions, and professional obligations relating to its use at trial.

Jordana Sanft | June 4, 2025

Women in IP Panel

Jordana Sanft was invited to speak at a joint event hosted by the Intellectual Property Society of Osgoode and the Osgoode Women's Network, titled Women in IP Panel. Jordana shared her insights on building a successful career in intellectual property law, strategies for professional growth, and navigating the path to senior leadership roles.

Jordana Sanft | March 3, 2025

Patent Agent Training Course: Infringement & Validity

Jordana Sanft was invited to share her expertise at the Intellectual Property Institute of Canada’s Patent Agent Training Course: Infringement & Validity. Jordana served as a lead instructor on the Virtual Lectures and Workshops on "Section 1: Patent Infringement", which took place from February 5-7. The program covered core principles of patent infringement and included hands-on exercises to deepen students' understanding of these key concepts.

Jordana Sanft | February 5, 2025

2024 Snapshot: Through the Lens of Lenczner Slaght

Lenczner Slaght launches our 2024 Snapshot, which highlights the most significant developments, decisions, and trends in litigation from the past year across 20 areas of expertise. Reflect on 2024 and look ahead to 2025 through the lens of our expert litigators.

February 1, 2025

Intellectual Property Commercialization

Jordana Sanft was invited to speak as a guest lecturer at Osgoode Hall Law School on the topic of Intellectual Property Enforcement.

Jordana Sanft | October 9, 2024

IPIC 2024 Conference

Jordana Sanft was invited to moderate the session, Inside the IP Chambers – A Federal Court Fireside Chat, at the IPIC 2024 Conference. Jordana led a discussion on the current challenges and triumphs in case management, trial management, and discoveries. The panel also explored issues and trends impacting IP practitioners and judicial officers in the Federal Court.

Jordana Sanft | September 26, 2024

Is Sharing a Hyperlink Copyright Infringement?

Jordana Sanft was invited to present at the ALAI Canada program titled, Is Sharing a Hyperlink Copyright Infringement? In this session, Jordana provided her expert insights on the implications of the BC Court of Appeal’s decision in Linkletter v Proctorio. Additionally, she compared the Canadian context to the events in the European Union where hyperlinking had led to major decisions from the EU Court of Justice.

Jordana Sanft | June 20, 2024

2023 Snapshot: Through the Lens of Lenczner Slaght

Lenczner Slaght launches our 2023 Snapshot, a look at the most significant developments, decisions, business takeaways, and trends in litigation from the last year, across 15 practice areas. Revisit 2023 and look ahead to 2024 through the lens of our expert litigators.

February 1, 2024

IPIC2023 Conference

Jordana Sanft was at the IPIC2023 Conference in Winnipeg. Jordana led a panel discussion on "What I Wish I Knew When I Was a Practitioner – Views from the Bench".

Jordana Sanft | October 12, 2023

Protecting Confidential Information

Jordana Sanft shared her expertise at the Intellectual Property Institute of Canada's webinar on Protecting Confidential Information – the Interplay between Implied Undertaking, Protective Orders/Agreements, and the Open Court Principle.

Jordana Sanft | June 27, 2023

Year-in-Review in IP Law 2023

Jordana Sanft was invited to speak at IPIC's Year-in-Review in IP Law 2023. Jordana presented a year-in-review on patent law and the significant decisions released over the last year.

Jordana Sanft | February 16, 2023

27th Intellectual Property Law: The Year in Review

Jordana Sanft was invited to share her expertise at the Law Society of Ontario's flagship program titled "27th Intellectual Property Law: The Year in Review". Jordana discussed key patents, trademarks, and copyright cases from 2022, along with opportunities linked to the new European unitary patent system and the Unified Patent Court.

Jordana Sanft | January 18, 2023

11th Annual Patent Colloquium

Jordana Sanft was invited to share her expertise at the University of Toronto's 11th Annual Patent Colloquium. Jordana spoke on the panel "AI’s Impact on Patent Law – Can AI Be the Inventor?".

Jordana Sanft | November 11, 2022

IPIC2022 Conference

Jordana Sanft was Chair of the IPIC2022 Conference in Whistler. Following her opening remarks to kick-off the conference, she led a conversation with the conference's keynote speaker, Manjit Minhas (CEO, Minhas Breweries, Distilleries and Wineries (Calgary) and Dragon, Dragon’s Den).

Jordana Sanft | September 29, 2022

Summer Courses in Intellectual Property

Jordana Sanft shared her expertise at the Intellectual Property Institute of Canada and McGill University Summer IP Course. Jordana presented on Patent Enforcement: Infringement and Mock Trial: Expert Reports and Cross-Examination of a Witness.

Jordana Sanft | July 19, 2022

Chambers Global (2020-2026)

Intellectual Property – Litigation (Canada)

Chambers Canada (2020-2026)

Intellectual Property: Litigation (Nationwide – Canada), Life Sciences: IP/Patent Litigation (Nationwide – Canada) (2022)

Canadian Legal Lexpert® Directory (2018-2026)

Intellectual Property (Most Frequently Recommended), Litigation - Intellectual Property (Consistently Recommended), Life Sciences & Health (Consistently Recommended)

Lexpert Special Edition: Canada's Leading Technology Lawyers (2021-2025)

Lexpert Special Edition: Canada's Leading Health Sciences Lawyers (2021-2025)

Best Lawyers in Canada (2015-2026)

Intellectual Property & Biotechnology and Life Sciences Practice

IAM Global Leader (2025-2026)

IAM Patent 1000 (2019-2020; 2022-2025)

Patent Litigation: Recommended Individual (Gold)

Lexology Index: Canada (2018-2026)

IP – Patents (Global Leader), Healthcare & Life Sciences – Patent Litigation (Global Leader), Healthcare & Life Sciences – Regulatory (Global Leader), Patents (National Leader), Patent Agents (National Leader), Life Sciences (National Leader), IP – Patent Agents & Attorneys (Global Leader)

Lexpert Guide to the Leading 500 Cross-Border Lawyers in Canada (2024-2026)

Intellectual Property